Trillium Therapeutics Inc. (TRIL): Price and Financial Metrics

Trillium Therapeutics Inc. (TRIL): $9.74

0.04 (+0.41%)

POWR Rating

Component Grades














  • Growth is the dimension where TRIL ranks best; there it ranks ahead of 89% of US stocks.
  • The strongest trend for TRIL is in Growth, which has been heading up over the past 31 weeks.
  • TRIL ranks lowest in Stability; there it ranks in the 8th percentile.

TRIL Stock Summary

  • TRIL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 6,036.27 -- higher than 99.27% of US-listed equities with positive expected earnings growth.
  • For TRIL, its debt to operating expenses ratio is greater than that reported by just 5.74% of US equities we're observing.
  • TRIL's price/sales ratio is 5,665.58; that's higher than the P/S ratio of 99.7% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Trillium Therapeutics Inc, a group of peers worth examining would be PINS, MELI, CVET, RDFN, and RPT.
  • TRIL's SEC filings can be seen here. And to visit Trillium Therapeutics Inc's official web site, go to

TRIL Price Target

For more insight on analysts targets of TRIL, see our TRIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.33 Average Broker Recommendation 1.42 (Moderate Buy)

TRIL Stock Price Chart Interactive Chart >

Price chart for TRIL

TRIL Price/Volume Stats

Current price $9.74 52-week high $20.96
Prev. close $9.70 52-week low $5.75
Day low $9.55 Volume 754,600
Day high $9.96 Avg. volume 1,346,486
50-day MA $9.26 Dividend yield N/A
200-day MA $12.31 Market Cap 1.00B

Trillium Therapeutics Inc. (TRIL) Company Bio

Trillium Therapeutics develops therapies for the treatment of cancer. The company was founded in 2004 and is based in Toronto, Canada.

TRIL Latest News Stream

Event/Time News Detail
Loading, please wait...

TRIL Latest Social Stream

Loading social stream, please wait...

View Full TRIL Social Stream

Latest TRIL News From Around the Web

Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.

Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies

Trillium Therapeutics Inc (NASDAQ: TRIL ) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including three new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure at the American Society of Hematology 2020 … Full story available on

Benzinga | April 28, 2021

Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021. The R&D Day agenda will include: a clinical update for TTI-622 and TTI-621,new strategic priorities in terms of target indications and drug combinations across hematologic malignancies and solid tumors, andupdated milestones and guidance for 2021. More information on Trillium’s R&D Day will be available at: You can join the webcast at:

Yahoo | April 22, 2021

Is TRIL Stock A Buy or Sell?

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Yahoo | April 8, 2021

How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?

The big shareholder groups in Trillium Therapeutics Inc. ( TSE:TRIL ) have power over the company. Insiders often own a...

Yahoo | April 6, 2021

These 3 Stocks Will Make You A Fortune If They Succeed

Unfortunately, capturing that type of gain typically means investing while the company is still small and its outcome is uncertain. Trillium Therapeutics (NASDAQ: TRIL), Vaxart (NASDAQ: VXRT), and Twist Biosciences (NASDAQ: TWST) have ambitions so big, they could produce these life-changing returns from the big-risk, big-reward portion of a diversified portfolio. Jan Skvarka, who Trillium introduced as CEO near the end of 2019, has said the company's long-term goal is to challenge chemotherapy.

Yahoo | April 1, 2021

Read More 'TRIL' Stories Here

TRIL Price Returns

1-mo 12.67%
3-mo -12.17%
6-mo -16.25%
1-year 27.49%
3-year 59.67%
5-year 1.88%
YTD -33.79%
2020 1,328.16%
2019 -39.77%
2018 -76.41%
2017 28.32%
2016 -55.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7999 seconds.